CELLCEPT 50MG – Composition, Uses and Medicine Enquiries
Product Overview
CELLCEPT 50MG is listed as a prescription product containing Mycophenolate mofetil 50MG, marketed in the source catalogue by Roche Products India Pvt Ltd.
It belongs to the immunosuppressant; antimetabolite class and is associated with the prevention of rejection after certain organ transplants, if the 50MG formulation is authentic.
Its active ingredient reduces the proliferation of immune cells involved in transplant rejection.
Important product verification: The supplied catalogue flags the 50MG CELLCEPT listing as unusual. The product must remain on hold until the exact pack, dosage form and strength are confirmed against original manufacturer packaging.
The dosage form must not be assumed to be a 50MG tablet.
Composition and Strength
The supplied product information identifies the following composition:
| Active Ingredient | Listed Strength |
|---|---|
| Mycophenolate mofetil | 50MG |
Product Name: CELLCEPT 50MG
Generic Name: Mycophenolate mofetil
Brand Name: CELLCEPT 50MG
Listed Strength: 50MG — verification required
Listed Marketer: Roche Products India Pvt Ltd
The exact strength and dosage form must be verified against the original manufacturer-labelled packaging before publication or any medicine enquiry.
Therapeutic Category and Indication
CELLCEPT 50MG is listed under the immunosuppressant category and the antimetabolite class.
The supplied information associates it with the prevention of rejection after certain organ transplants, if the 50MG formulation is authentic.
Mycophenolate mofetil reduces the proliferation of immune cells involved in transplant rejection.
Treatment choice depends on the confirmed diagnosis, previous treatment, organ function and other medicines. The benefit-risk balance, approved use and monitoring plan must be determined by the treating specialist.
Major pregnancy risks, infections and blood count changes require close monitoring.
Administration Information
The exact route of administration and dosage form have not been confirmed in the supplied product information.
The product must not be assumed to be a 50MG tablet.
Patients should follow only the treating clinician’s instructions and the approved product label. They should not independently adjust the dose, skip safety monitoring or switch formulations without medical advice.
The dosage form and administration schedule must be verified before publication.
Product Presentation and Availability
The product enquiry can be identified using the following supplied details:
- Product Name: CELLCEPT 50MG
- Generic Name: Mycophenolate mofetil
- Listed Strength: 50MG
- Company Name: Roche Products India Pvt Ltd
- Therapeutic Category: Immunosuppressant
- Medicine Class: Antimetabolite
- Indication: Prevention of rejection after certain organ transplants, if the formulation is authentic
- Dosage Form: Requires verification
The supplied catalogue specifically flags the 50MG listing as unusual.
The exact manufacturer pack, formulation, dosage form, pack size, batch, storage and expiry must be verified against original manufacturer packaging and an authorised provider.
Publication status: Keep this product on hold until the listed strength and formulation are confirmed.
Prescription and Patient Safety
CELLCEPT 50MG is listed as a prescription product and requires specialist assessment.
Treatment suitability, contraindications, interactions and monitoring requirements must be evaluated by the treating specialist.
Major pregnancy risks, infections and blood count changes require close monitoring.
The exact product presentation must be confirmed before any treatment-related information or medicine enquiry is processed.
Medicine Enquiry Coordination Through Medinglobal
Medinglobal is a healthcare coordination platform. It can receive medicine information requests and, where legally permissible, connect patients or institutions with appropriately authorised independent pharmaceutical providers.
Medinglobal does not itself sell, dispense, manufacture or export medicines.
Product availability, lawful supply, prescription validation, commercial terms and destination requirements must be verified by the independent provider. Submitting an enquiry does not guarantee fulfilment.
How to Submit a CELLCEPT 50MG Enquiry
To help identify the requested product, include the following details:
- Product name: CELLCEPT 50MG.
- Generic name: Mycophenolate mofetil.
- Required strength: 50MG, subject to verification.
- Exact dosage form and product packaging.
- Required quantity.
- Destination country.
- Valid prescription or institutional documents, where required.
The exact product presentation must be confirmed before the enquiry can be accurately processed.
Medinglobal may coordinate an introduction to a suitably authorised provider. The provider independently verifies product details, regulatory eligibility and any transaction.
Frequently Asked Questions
What is CELLCEPT 50MG listed for?
The supplied information associates it with the prevention of rejection after certain organ transplants, if the 50MG formulation is authentic. The prescriber must confirm the approved use.
What is the composition of CELLCEPT 50MG?
The supplied catalogue lists Mycophenolate mofetil 50MG. The composition and strength must be verified against the original product packaging.
Is CELLCEPT 50MG a tablet?
The supplied information does not confirm the dosage form. It must not be assumed to be a 50MG tablet.
Which company is listed for CELLCEPT 50MG?
Roche Products India Pvt Ltd is listed as the marketer in the supplied product information.
Why does CELLCEPT 50MG require verification?
The supplied catalogue specifically flags the 50MG listing as unusual and requires confirmation of the exact pack, dosage form and strength.
Can Medinglobal supply CELLCEPT 50MG directly?
No. Medinglobal coordinates medicine enquiries with independent authorised providers where legally permissible.



Reviews
There are no reviews yet.